Purification of gene and cell therapy vectors such as AAV, lentivirus, and exosomes, is based on legacy technologies which were originally designed for monoclonal antibody bioseparation.
The limitations of resin-based chromatography for large cell and gene therapy modalities include:
- Long processing times
- Low binding capacities
- High associated costs
As cell and gene therapies become more accessible, new approaches are required to ensure the purity and volume of these novel therapeutics. Through our development of an unprecedented and proprietary fiber-based technology, we’re able to empower therapeutic innovators with the tools they need to purify the quantities they desire.
Using anion exchange chromatography for lentivirus purification, we can provide a high concentration without ultracentrifugation or time-consuming filtration by hand, accelerating the path to purified lentivirus preparation.
To address this need, Astrea Bioseparations has developed a novel, state-of-the-art, fiber-based bioprocessing technology to advance vector purification with:
- Faster Processing Times
- Immediate access to binding surface area, eliminating long residence times
- High flow rates advanced by an electrospun matrix
- Higher Process Yields
- Up to 10x increase in binding capacity due to large accessible surface area
- Increased infectivity, due to lower process stressors